Diagnostic Value between 1984 and 2018 of Transrectal Biopsy Guided by Ultrasonography after Radical Prostatectomy

Luiz Carlos de Araújo Souza¹, Vinícius Carvalhêdo Cunha¹, Hugo Oliveira de Figueiredo Cavalcanti², João Ricardo Alves³, Grimar de Oliveira Paula⁴ and Sandra Lúcia Branco Mendes Coutinho⁵

¹. Undergraduates of Medicine in the University Center of Brasilia (UniCEUB)
². Physician Anatomopathologist by Hospital Base of the Federal District (HBDF)
³. Physician Urologist of the Clinical Body of the Hospital Base of the District Federal and Urocentro (HBDF)
⁴. Physician Urologist by Hospital Base of the Federal District (HBDF)
⁵. Physician Anatomopathologist and Head of the Department of Cytopathology and Anatomical Pathology of the Hospital Base of the Federal District (NUCAP-HBDF)

Abstract: Objectives—to determine correlation between GSs (Gleason scores) on needle biopsy and RP (radical prostatectomy), evaluating diagnostic tests on biopsy and RP within the last years, between 1984 and 2018. Method—analysis of 100 patients, diagnosed with PCa (prostate cancer) needle biopsy using 18-gauge needle, who underwent RP with lymphadenectomy and for which preoperative and postoperative GSs were available. GS group analysis used three categorization schemes for differentiation: mild, moderate and poor for the whole group and we determined SE (sensitivity), SP (specificity), PVPR (positive predictive value), negative predictive value and accuracy. Results—we found that 42% of the patients had no changes between GS on biopsy and prostatectomy, while 20% were overgraded and 38% undergraded by needle biopsy. Graduation of +1 point in GS (32%) or -1 point (17%) was the most common. Most patients were classified as moderately differentiated by biopsies (78 and 35% in scheme 1 and 2 or 3, respectively), while 43% of patients received an intermediate differentiation classification. Biopsy accuracy varied from 44 to 76% for the analysis of all three schemes. Conclusion—there are differences in correlation between GS on biopsy and on surgical specimen, and Gleason’s graduation also depends on the experience of the pathologist. We have shown that sextant biopsies using 18-gauge and a same group of pathologists showed acceptable concordance values (42%) between the GS on biopsy and prostatectomy.

Key words: PCa, transrectal biopsy guided by ultrasonography, RP, PSA (prostate specific antigen).

1. Introduction

(PCa) Prostate cancer is the second most diagnosed neoplasm in men and the second-leading cause of cancer death in men worldwide. There were estimated 1.1 million new cases, about 15% of male cancers, were estimated in 2012 in the latest worldwide estimate [1, 2].

Diagnosis is made through analysis of fragments obtained by prostate biopsy guided by ultrasonography, motivated by (PSA) prostatic specific antigen level changes and abnormalities found in DRE (Rectal Digit Exam) [3-6].

Two very important prognostic factors are staging, performed by AJCC’s TNM system, and GS (Gleason score) [7, 8]. These factors are determinant for patient risk classification and for correct therapeutic decision making, radiotherapy and RP (radical prostatectomy) are the main treatments for PCa without metastasis [9, 10].

However, some studies have shown that in about 33% of patients, there is an incongruence between GS after
RP when compared to biopsy [11-16]. And this divergence could be influenced by some factors such as: needle gauge; amount of biopsied tissue; percentage of neoplastic tissue and variation of the interobserver analysis or intraobserver variation [5, 11-16].

This study aims to determine the correlation between Gleason scores on needle biopsy and RP, evaluating biopsy and RP diagnostic tests within the last years, between 1984 and 2018.

2. Materials and Methods

2.1 Ethical Conditions

The present study was approved by the Research Ethics Committee of the Hospital Base of the District Federal, Brasília, CAAE: 93792918.8.0000.8153.

2.2 Patients and Data Collection

A retrospective study was carried out analyzing from 2013 to 2017 a total of 100 patients diagnosed with prostate adenocarcinoma by biopsy and performed RP with lymphadenectomy. The information was collected from electronic medical records and anatomopathological reports. Biopsy indication took into account PSA level changes (> 2.5-4 ng/mL) and EDR [17-19]. Transrectal image of the prostate was obtained with a sectorial transducer for subsequent biopsy collection, the samples obtained by puncture were sextants at least 12 fragments using 18-gauge needle (18-Gauge). These fragments were sent for anatomopathological study, being stained with HE (hematoxylin and eosin) and graduation according to the Gleason methods by the same group of pathologists. Subsequently, all patients diagnosed with adenocarcinoma and with surgical indications were treated with RP with lymphadenectomy. Surgical specimens were sent to anatomopathological study and submitted to several histological sections, thus, determined pathological GS, the greater diameter of the prostate; measurement in centimeters (cm) of prostate’s length, width and height to calculate prostate’s volume (length × height × width × π/6); angiolymphatic invasion; perineural invasion, seminal vesicle invasion, extraprostatic extension; bladder and urethral surgical margins; pTNM pathological staging.

2.3 Statistical Analysis

The analyzed variables were computed using SPSS version 20.0. GSs of biopsy and RP were correlated. When we analyzed the GSs on biopsy and RP, we used the crosstabs to determine how many biopsies had undergraded, matched, and overgraded. We determined SE (sensitivity), SP (specificity), PVPR (positive predictive value), negative predictive value and accuracy of biopsies with GS of the surgical specimen as the gold standard.

3. Results

Our study analyzed 100 patients diagnosed with prostate adenocarcinoma who underwent RP with lymphadenectomy. Regarding age of the patients, the mean was 64.97 years, median of 65 years and age ranging from 45 to 77 years (Table 1). Preoperative PSA presented a mean of 14.74 ng/mL and when patients were classified as PSA < 10 ng/mL, they accounted for 49% of the sample, between 10-20 ng/mL, 40% of the sample and > 20 ng/mL added up to 11% of the sample. About 45% of the patients received cT1 clinical staging, 53% cT2 staging and 2% cT3 staging. When we analyzed the sum of GSs on biopsy, we found that 35% of the patients had a sum of 6, 43% had a sum of 7, 17% had a sum of 8 and 5% had a sum of 9. However, after RP and subsequent analysis of pathological Gleason score, 3% of patients had a sum of 6, 87% had a sum of 7, 3% had a sum of 8 and 7% had a sum of 9.

After macroscopic evaluation of the prostate for anatomopathological analysis, the largest diameter of the prostate was measured (cm) and the patients were classified in < 5 cm (40%) and≥ 5 cm (60%). We measured the length, width, and height of the prostate for calculating prostate volume (length × height × width × π/6), patients were classified as < 80 cm³ (53%).
Diagnostic Value between 1984 and 2018 of Transrectal Biopsy Guided by Ultrasonography after Radical Prostatectomy

| Variable                                      | All patients $n = 100$ (%) |
|-----------------------------------------------|----------------------------|
| **Age (years)**                               | Mean 64.97                 |
|                                               | Median 65                  |
|                                               | Range 45-77                |
| **Preoperative PSA (ng/mL)**                  | Mean 14.74                 |
|                                               | Median 10                  |
|                                               | Range 2.9-281              |
| **PSA divisions (ng/mL)**                     | < 10 49 (49.0%)            |
|                                               | 10-20 40 (40.0%)           |
|                                               | > 20 11 (11.0%)            |
| **cT stage**                                  | T1 45 (45.0%)              |
|                                               | T2 53 (53.0%)              |
|                                               | T3 2 (2.0%)                |
| **Primary biopsy Gleason**                    | 3 72 (72.0%)               |
|                                               | 4 28 (28.0%)               |
| **Secondary biopsy Gleason**                  | 3 42 (42.0%)               |
|                                               | 4 52 (52.0%)               |
|                                               | 5 6 (6.0%)                 |
| **Biopsy Gleason sum**                        | 6 35 (35.0%)               |
|                                               | 7 (3 + 4) 36 (36.0%)       |
|                                               | 7 (4 + 3) 7 (7.0%)         |
|                                               | 8 17 (17.0%)               |
|                                               | 9 5 (5.0%)                 |
| **Primary pathological Gleason**              | 3 58 (58.0%)               |
|                                               | 4 41 (41.0%)               |
|                                               | 5 1 (1.0%)                 |
| **Secondary pathological Gleason**            | 3 35 (35.0%)               |
|                                               | 4 59 (59.0%)               |
|                                               | 5 6 (6.0%)                 |
| **Pathological Gleason sum**                  | 6 3 (3.0%)                 |
|                                               | 7 (3 + 4) 55 (55.0%)       |
|                                               | 7 (4 + 3) 32 (32.0%)       |
|                                               | 8 3 (3.0%)                 |
|                                               | 9 7 (7.0%)                 |
| **Greatest pathological measure of the prostate** | < 5 cm 40 (40.0%)         |
|                                               | ≥ 5 cm 60 (60.0%)          |
| **Estimated prostate volume (cm³)**           | < 80 cm³ 53 (53.0%)        |
|                                               | ≥ 80 cm³ 47 (47.0%)        |
| **Surgical specimens data (invasions)**       | (Present/Neoplastic free/Not evaluated) |
|                                               | Angiolymphatic 10 (10.0%)/51 (51.0%)/39 (39.0%) |
|                                               | Perineural 94 (94.0%)/6 (6.0%)/0 (0.0%) |
|                                               | Right seminal vesicle 14 (14.0%)/83 (83.0%)/3 (3.0%) |
|                                               | Left seminal vesicle 17 (17.0%)/80 (80.0%)/3 (3.0%) |
|                                               | Extra-prosthetic extension 45 (45.0%)/52 (52.0%)/3 (3.0%) |
|                                               | Vesical surgical margins 8 (8.0%)/90 (90.0%)/2 (2.0%) |
|                                               | Urethral surgical margin 17 (17.0%)/79 (79.0%)/4 (4.0%) |
and ≥ 80 cm³ (47%). When we analyzed the perineural invasion, we found that 94% of patients had perineural invasion present. The left seminal vesicle was affected in 17% of the cases, and the right in 14% of the cases, showing a major involvement in the left seminal vesicle. Extra-prostatic extension was observed in 45% of the patients analyzed. The analyzed margins showed that 8% of the patients had involvement of bladder margin and 17% of the patients had involvement of the urethral margin, evidencing a greater involvement of the urethral margin. After TNM staging, 3% of the patients had pT2a, 5% pT2b staging, 42% pT2c staging, 30% pT3a staging, 20% pT3b staging. About 93% of the patients presented pN0 staging and 7% of patients presented pN1 staging. A total of 805 lymph nodes (mean of 8.05 lymph nodes and standard deviation of 4.69) were removed for analysis and only 10 lymph nodes (mean of 0.10 and standard deviation of 0.41) were affected by neoplasia.

### 3.1 Analysis of the Correlation between GS on Biopsy and Surgical Specimen

The correlation between biopsy and RP GSs showed an exact match in 42% of all patients, had no alterations in the attribution of punctuation, while 20% were overgraded and 38% undergraded by needle biopsy (Table 2). Based on biopsy analysis, most patients had a GS of 6 (35%), 7 (43%) or 8 (17%). Based on the analysis of surgical specimen, the majority had a GS of 7 (87%) and 9 (7%). Based on biopsies, while 35% of patients had a GS of 6, only 3% of the patients with a GS of 6 remained in the RP specimens.

Fig. 1 shows a histogram based on the differences between the two attributions of GS calculated as [(GS of RP with lymphadenectomy) - (GS of ultrasound-guided transrectal biopsy)]. The results with a positive difference reflect undergraded biopsy, while a negative difference reflects overgraded biopsy. When we analyzed data from Fig. 1, we showed that 42% of the patients evaluated had no change in the attribution of GS. A total of 20% of the patients were overgraded by biopsy, while 38% were undergraded by biopsy. The graduation of +1 point in the GS (32%) or -1 point (17%) were the most common.

When we analyzed correlation between the GS categories (well, moderate and poorly differentiated) for biopsies and prostatectomy specimens for three different categorization schemes (Scheme 1: GS 2-4, 5-7, 8-10, Scheme 2: GSs 2-4, 5-6, 7-10 and Scheme 3: GS 2-4, 5-6, 7 and 8-10) (Table 3), no patient was classified as well differentiated (GS 2-4). Most patients were classified as moderately differentiated by biopsies (78 and 35% in scheme 1 and 2 or 3, respectively), while 43% of patients received an intermediate differentiation score (Gleason 7). Regardless of the scheme used to analyze biopsies, between 22% (Schemes 1 and 3) and 65% (Scheme 2) of the patients were categorized as poorly differentiated. When we analyzed prostatectomy samples, we showed that 10% (Schemes 1 and 3) and 97% (Scheme 2) of the patients were categorized as poorly differentiated, with a total of 87% receiving a GS 7 (intermediate differentiated).
Table 2  Correlation between individual GSs based on biopsy and prostatectomy specimens.

| Biopsy specimen | GS 6 | 7 | 8 | 9 | All |
|-----------------|------|---|---|---|-----|
| 6               | 1    | 32| 1 | 1 | 35 (35%) |
| 7               | 2    | 37| - | 4 | 43 (43%) |
| 8               | -    | 15| 2 | - | 17 (17%) |
| 9               | -    | 3 | - | 2 | 5 (5%) |
| All             | 3    | 87| 3 | 7 | 100 |

% (3%) (87%) (3%) (7%) (100%)

Fig. 1 Histogram with the differences between biopsy score and RP score. The value of 0 (x-axis) means all the patients who agreed, the others are positive and negative differences found. The percentage (axis y) of patients with observed differences and the total number of patients with observed differences (above the x-axis columns).
Table 3  Correlation of GS between biopsy and prostatectomy specimen based on GS categories using three different categorization schemes.

| Categorization scheme 1 | Biopsy categories | RP specimen categories | All (%) |
|-------------------------|-------------------|------------------------|---------|
|                         |                   | Well | Moderate | Poor |            |
| Well (2–4)              | -                 | -    | -        | -    |            |
| Moderately (5–7)        | -                 | 72 (72.0) | 6 (6.0) | 78 (78.0) |
| Poorly (8–10)           | -                 | 18 (18.0) | 4 (4.0) | 22 (22.0) |
| All (%)                 | -                 | 90 (90.0) | 10 (10.0) | 100 (100) |

| Categorization scheme 2 | Biopsy categories | RP specimen categories | All (%) |
|-------------------------|-------------------|------------------------|---------|
|                         |                   | Well | Moderate | Poor |            |
| Well (2–4)              | -                 | -    | -        | -    |            |
| Moderately (5–6)        | -                 | 1 (1.0) | 34 (34.0) | 35 (35.0) |
| Poorly (7–10)           | -                 | 2 (2.0) | 63 (63.0) | 65 (65.0) |
| All (%)                 | -                 | 3 (3.0) | 97 (97.0) | 100 (100) |

| Categorization scheme 3 | Biopsy categories | RP specimen categories | All (%) |
|-------------------------|-------------------|------------------------|---------|
|                         |                   | Well | Moderate | Intermediate | Poor |            |
| Well (2–4)              | -                 | -    | -        | -        | -    |            |
| Moderately (5–6)        | -                 | 1 (1.0) | 32 (32.0) | 2 (2.0) | 35 (35.0) |
| Intermediate (7)        | -                 | 2 (2.0) | 37 (37.0) | 4 (4.0) | 43 (43.0) |
| Poorly (8–10)           | -                 | 0 (0.0) | 18 (18.0) | 4 (4.0) | 22 (22.0) |
| All (%)                 | -                 | 3 (3.0) | 87 (87.0) | 10 (10.0) | 100 (100.0) |

The table shows the number of patients and their respective percentages for each type of scheme. Scheme 1: GSs 2-4 = well; 5-7 = moderate; 8-10 = poor. Scheme 2: GSs 2-4 = well; 5-6 = moderate; 7-10 = poor. Scheme 3: GSs 2-4 = well; 5-6 = moderate; 7 = intermediate; 8-10 = poor.

Table 4  SE, SP, predictive value of a positive result (PVPR), predictive value of a negative result (PVNR), and accuracy (ACCU) for the biopsy score category to predict the radical score category for the three categorization schemes.

| Score | Category | SE (%) | SP (%) | PVPR (%) | PVNR (%) | ACCU (%) |
|-------|----------|--------|--------|----------|----------|----------|
| 2–4   | Well     | -      | -      | -        | -        | -        |
| 5–7   | Moderate | 80.0   | 40.0   | 92.3     | 18.2     | 76.0     |
| 8–10  | Poor     | 40.0   | 80.0   | 18.2     | 92.3     | 76.0     |

When we analyze the SE, SP, PVPR, negative predictive value (PVNR) and accuracy (ACCU) for each type of scheme (1, 2 and 3), we show that SE is very low for the categories of moderate biopsy in schemes 2 and 3, while SP is poor for the category of poor biopsy in scheme 2 (Table 4). Similarly, PVPR is very low for the category of moderate and poor biopsies (schemes 1 and 3) and the PVNR is very low for the poor and intermediate biopsy (Schemes 2 and 3). The ACCU of the samples varied from 44 to 76% for
the analysis of all three schemes.

4. Discussion

PCa is the second most prevalent cancer in the male population worldwide, affecting patients usually above 50 years old, being uncommon under 40, advanced age comprises a well-established risk factor, since both the incidence and mortality increase after 50 years old [1, 2, 20]. Roche et al. [21] after analyzing 606 retropubic radical prostatectomies, showed a mean age of this group of 65 years old and mean preoperative PSA of 12.8 ng/mL. Patients in the present study presented variations from 45 to 77 years old, mean of 64.97 years old (Table 1).

Several studies report that the prognosis of patients diagnosed with prostate adenocarcinoma is associated with histopathological parameters, such as staging, histological grade, GS and state of the surgical margins, as well as age and PSAdosage [22-26]. Our study, when grouping preoperative PSA values between (< 10, 10-20, > 20 ng/mL) found that about 49% of patients had a PSA level < 10 ng/mL. Some studies have determined the perineural invasion as the main mechanism of neoplastic dissemination beyond the prostate, and it is found in 17% to 38% of the cases [27-29]. Vascular invasion may be present in about 38% of cases of RP due to adenocarcinoma, being associated with extraprostatic extension, lymph node metastases, histological grade and staging. Metastases are more often found in bone tissue and regional lymph nodes [24, 30-35]. Eduardo et al. [22] after examining 118 radical prostatectomies, showed that GS 6 was the most frequent (46.61% of the cases), being associated with extraprostatic extension, however, the presence of nodal metastases is associated with a GS ≥ 7. When we analyzed perineural invasion, we found that 94% of the patients had perineural invasion present. Angiolymphatic invasion was present in 10% of patients (Table 1). We observed more often involvement in the left seminal vesicle (17%) followed by the right one (14%) and extraprostatic extension was evident in 45% of the patients analyzed. We observed more often involvement of the urethral margin (17%) followed by the bladder margin (8%).

Several studies have attempted to evaluate the concordance between GSs on biopsy and surgical specimen [36-52]. The major difficulties encountered in the exact evaluation are: sub-gradation or over-gradation of GSs on ultrasound-guided transrectal biopsy and surgical specimen, and possible factors contributing to this inconsistency, including pathological interpretation, sampling error, number of biopsies collected, and quantity of cancer within the collected biopsy material [48]. In Table 5, previous studies of the last 22 years totaled 7,021 patients comparing GS of the biopsy and RP using 18-gauge needle with different pathologists or even a group of pathologists. The weighted mean, showed an exact match in 53%, a difference of ± 1 unit in 34%, a difference of ± 2 units in 13%, overgrade in 12% and subgrade in 35% [36-52]. In Table 5, when we divided the patients according to categorization scheme 3 (Table 3), we showed an exact match in 62%, overgrade in 9% and subgrade in 29%. Our study presented a 42% exact match between Gleason on biopsy and prostatectomy scores, a difference of ± 1 unit in 49%, a difference of ± 2 units in 9%, overgrade in 20% and a subgrade in 38% (Tables 2-5). The GS difference between the exact match is shown in Fig. 1, which shows a higher prevalence of graduation of +1 point (32%) and -1 point (17%) in the sample analyzed.

Even though there is no universal consensus regarding the categorization of GS divisions, several categorization schemes are widely used (Table 3). Literature classifies a GS between 2-4 as well differentiated, GSs between 8-10 are classified, in most studies, as poorly differentiated. The scientific debate revolves around the classification of GSs between 5-6 which are labeled moderately and GSs equal to 7 that are labeled as intermediate differentiation [65, 66]. In Table 6, 31,147 patients were grouped according to the type 3 scheme (Table 3), showing that 55.0% of the
| Author          | Year | No. of patients | Comparisons between biopsy and prostatectomy Gleason grades (%) | Correlation of biopsy and surgical score of Gleason by assignment of the Categorization scheme 3 |
|-----------------|------|-----------------|----------------------------------------------------------------|--------------------------------------------------|
|                |      |                 | % Difference exact correlation (%) | % Difference ± 1 unit (number/total) | % Difference ± 2 (number/total) | Needle overgrade (number/total) | Needle undergrade (number/total) | % Exact correlation (%) | Needle overgrade (number/total) | Needle undergrade (number/total) |
| Thickman et al. | 1996*| 124             | 28 (35/124) | 34 (42/124) | 38 (47/124) | 15 (18/124) | 57 (71/124) | 44 (54/124) | 9 (11/124) | 48 (59/124) |
| Cookson et al.  | 1997*| 226             | 31 (70/226) | 43 (97/226) | 26 (59/226) | 15 (33/226) | 54 (123/226) | 46 (104/226) | 8 (19/226) | 46 (103/226) |
| Steinberg et al.| 1997*| 390             | 34 (131/390) | 34 (133/390) | 32 (126/390) | 6 (25/390) | 60 (234/390) | 45 (175/390) | 5 (21/390) | 50 (194/390) |
|                | 1997**| 499             | 58 (291/499) | 36 (181/499) | 6 (27/499) | 6 (30/499) | 36 (178/499) | 66 (329/499) | 4 (22/499) | 30 (148/499) |
| Danziger et al. | 1997*| 100             | 34             | 38             | 28             | 17             | 49             | 51             | 10             | 39             |
|                | 1997**| 100             | 42             | 43             | 15             | 22             | 36             | 49             | 17             | 34             |
| Djavan et al.  | 1998*| 415             | 37 (154/415) | 37 (153/415) | 26 (108/415) | 13 (53/415) | 50 (208/415) | 52 (214/415) | 7 (31/415) | 41 (170/415) |
| Carlson et al. | 1998**| 106             | 68 (72/106) | 29 (31/106) | 3 (3/106) | 8 (8/106) | 25 (26/106) | 70 (74/106) | 6 (6/106) | 25 (26/106) |
| Cury et al. [42]| 1999**| 120             | 33 (39/120) | 30 (36/120) | 37 (45/120) | 5 (6/120) | 62 (75/120) | 51 (61/120) | 2 (2/120) | 47 (57/120) |
| King [43]      | 2000*| 428             | 41 (177/428) | 42 (178/428) | 17 (73/428) | 17 (71/428) | 42 (180/428) | 51 (219/428) | 14 (61/428) | 35 (148/428) |
| Fukagai et al. | 2001**| 116            | 46 (53/116) | 46 (53/116) | 9 (10/116) | 8 (9/116) | 47 (54/116) | 56 (65/116) | 4 (5/116) | 40 (46/116) |
| Lattouf and Saad [45] | 2002* | 393 | 29 (115/393) | 45 (176/393) | 26 (102/393) | 32 (127/393) | 38 (151/393) | 48 (190/393) | 20 (79/393) | 32 (124/393) |
| San Francisco et al. [46] | 2003** | 340 | 69 (233/340) | 29 (98/340) | 3 (9/340) | 6 (22/340) | 25 (85/340) | 76 (257/340) | 10 (35/340) | 14 (48/340) |
| Emiliozzi et al. [47] | 2004** | 89 | 49 (44/89) | 37 (33/89) | 13 (12/89) | 11 (10/89) | 39 (35/89) | 58 (52/89) | 10 (9/89) | 29 (26/89) |
| Divrik et al. [48] | 2007* | 186 | 41 (76/186) | 45 (84/186) | 14 (26/186) | 22 (40/186) | 38 (70/186) | 56 (104/186) | 12 (22/186) | 32 (60/186) |
| Moreira et al. [49] | 2008** | 464 | 57 (264/464) | 34 (160/464) | 9 (40/464) | 14 (65/464) | 29 (135/464) | 65 (301/464) | 12 (58/464) | 23 (105/464) |
### Table 5 continued

| Author               | Year | No. of patients | Exact correlation (%) | % Difference by ± 1 unit (number/total) | % Difference by ± 2 (number/total) | Needle overgrade (number/total) | Needle undergrade (number/total) | % Exact correlation (number/total) | Needle overgrade (number/total) | Needle undergrade (number/total) |
|----------------------|------|----------------|-----------------------|----------------------------------------|-----------------------------------|---------------------------------|---------------------------------|----------------------------------|---------------------------------|----------------------------------|
| Kvåle et al. [50]    | 2009*| 1,116          | 53                    | (591/1,116)                            | 37 (412/1,116)                    | 10 (113/1,116)                  | 9 (106/1,116)                   | 38 (419/1,116)                   | 60 (673/1,116)                   | 6 (68/1,116)                      | 34 (375/1,116)                   |
| Moussa et al. [51]   | 2009*| 1,129          | 76                    | (862/1,129)                            | 20 (223/1,129)                    | 4 (44/1,129)                    | 12 (136/1,129)                  | 12 (131/1,129)                   | 80 (904/1,129)                   | 11 (129/1,129)                   | 9 (96/1,129)                     |
| Helpap et al. [52]   | 2016**| 580            | 74                    | (430/580)                              | 24 (138/580)                      | 2 (12/580)                      | 4 (21/580)                      | 22 (129/580)                     | 74 (431/580)                     | 4 (20/580)                       | 22 (129/580)                     |
| **Current study**    |      | **100**        | **53**                | **34**                                 | **13**                            | **12**                          | **35**                          | **62**                           | **9**                           | **29**                           |
| Overall (weighted mean %) |     | **7,021**   | **53**                | **34**                                 | **13**                            | **12**                          | **35**                          | **62**                           | **9**                           | **29**                           |

*18-Gauge, sextant, different pathologists; **18-Gauge, sextant, same (group) pathologist(s).

### Table 6
Comparison of studies that have distributed the GSs of biopsy and surgery in well, Moderately, intermediate and poorly.

| Author               | Year  | No. of patients | Biopsy GS group assignment | Prostatectomy GS group assignment |
|----------------------|-------|----------------|----------------------------|-----------------------------------|
|                      |       |                | Well (2-4) | Moderately (5-6) | Intermediate (7) | Poorly (8-10) | Well (2-4) | Moderately (5-6) | Intermediate (7) | Poorly (8-10) |
|                      |       |                | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % | Number | % |
| Garnett et al. [53]  | 1984* | 115            | 24     | 20.9 | 75     | 65.2 | 11     | 9.6 | 5     | 4.3 | 14     | 12.2 | 70     | 60.9 | 25     | 21.7 | 6     | 5.2 |
| Mills and Fowler     | 1986* | 38             | 8      | 21.1 | 15     | 39.5 | 10     | 26.3 | 5     | 13.2 | 3     | 7.9 | 8      | 21.1 | 16     | 42.1 | 11     | 28.9 |
| Thickman et al. [36] | 1996* | 124            | 41     | 33.1 | 59     | 47.6 | 22     | 17.7 | 2     | 1.6 | 13     | 10.5 | 62     | 50   | 38     | 30.6 | 11     | 8.9 |
| Cookson et al. [37]  | 1997* | 226            | 37     | 16.4 | 128    | 56.6 | 47     | 20.8 | 14    | 6.2 | 5     | 2.2 | 109    | 48.2 | 85     | 37.6 | 27     | 11.9 |
| Steinberg et al. [38]| 1997* | 390            | 87     | 22.3 | 220    | 56.4 | 70     | 17.9 | 13    | 3.3 | 1     | 0.3 | 188    | 48.2 | 176    | 45.1 | 25     | 6.4 |
| Djavan et al. [40]   | 1998* | 415            | 97     | 23.4 | 240    | 57.8 | 69     | 16.7 | 9     | 2.2 | 31     | 7.5 | 232    | 55.9 | 116    | 27.9 | 36     | 8.7 |
| Carlson et al. [41]  | 1998* | 106            | 0      | 0     | 82     | 77.4 | 24     | 22.6 | 0     | 0    | 1     | 0.9 | 62     | 58.5 | 41     | 38.7 | 2     | 1.9 |
| Author                  | Year | No. of patients | Biopsy GS group assignment | Prostatectomy GS group assignment |
|-------------------------|------|-----------------|-----------------------------|-----------------------------------|
|                         |      | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  | Number | %  |
|                         |      | Well (2-4) | Moderately (5-6) | Intermediate (7) | Poorly (8-10) | Well (2-4) | Moderately (5-6) | Intermediate (7) | Poorly (8-10) |
| King [43]               | 2000*| 428     | 26 | 6.1   | 204 | 47.7 | 135 | 31.5 | 63 | 14.7 | 8 | 1.9 | 153 | 35.7 | 188 | 43.9 | 79 | 18.5 |
| Fukagai et al. [44]     | 2001*| 116     | 10 | 8.6   | 59  | 50.9 | 27  | 23.3 | 20 | 17.2 | 1 | 0.9 | 37  | 31.9 | 53  | 45.7 | 25 | 11.6 |
| Lattouf et al. [45]     | 2002*| 393     | 70 | 17.8  | 241 | 61.3 | 64  | 16.3 | 18 | 4.6  | 66 | 16.8 | 201 | 51.1 | 99  | 25.2 | 27 | 6.9  |
| San Francisco et al. [46]| 2003*| 340     | 2  | 0.6   | 96  | 76.2 | 20  | 15.9 | 10 | 7.9  | 0 | 0    | 91  | 72.2 | 19  | 11   | 0  | 0    |
| Emiliozzi et al. [47]   | 2004*| 89      | 8  | 9     | 49  | 55.1 | 26  | 29.2 | 6  | 6.7  | 1 | 1    | 42  | 47.2 | 38  | 42.7 | 8  | 9    |
| King et al. [55]        | 2004*| 78      | 0  | 0     | 19  | 24.4 | 45  | 57.7 | 14 | 17.9 | 0 | 0    | 22  | 28.2 | 50  | 64.1 | 6  | 7.7  |
| Chun et al. [56]        | 2006*| 3,107   | 61 | 2     | 2,050 | 66 | 880  | 28.3 | 116 | 3.7 | 7  | 0.2 | 1,397 | 45 | 1,606 | 51.7 | 97 | 3.1  |
|                        | 2006**| 1,682  | 29 | 1.7   | 1,156 | 68.7 | 440 | 26.2 | 57 | 3.4 | 8  | 0.4 | 797  | 47.4 | 812 | 48.3 | 65 | 3.9  |
| Divrik et al. [48]      | 2007*| 186     | 10 | 5.4   | 112  | 60.2 | 46  | 24.7 | 18 | 9.7  | 8  | 4.3 | 78   | 41.9 | 72  | 38.7 | 28 | 15.1 |
|                        | 2007**| 206    | 20 | 9.7   | 114  | 55.3 | 44  | 21.4 | 28 | 13.6 | 4 | 1.9 | 98   | 47.6 | 66  | 32   | 38 | 18.4 |
| Fine et al. [57]        | 2008*| 1,455   | 23 | 1.6   | 1,057 | 72.6 | 343 | 23.6 | 32 | 2.2  | 0  | 0    | 978  | 67.2 | 406 | 27.9 | 71 | 4.9  |
| Moreira et al. [49]     | 2008*| 464     | 2  | 0.4   | 179  | 38.6 | 177 | 38.2 | 106 | 22.8 | 0  | 0    | 137  | 29.6 | 202 | 43.5 | 125| 26.9 |
| Moussa et al. [51]      | 2009*| 1,129   | 0  | 0     | 0    | 0    | 960 | 85   | 169 | 15  | 0  | 0    | 63   | 5.6  | 869 | 76.9 | 197| 17.5 |
| Fanning et al. [58]     | 2009**| 206   | 0  | 0    | 0    | 0    | 110 | 53.4 | 79  | 38.4 | 17 | 8.2 | 64   | 31   | 116 | 56.3 | 26 | 12.7 |
| Kvåle et al. [50]       | 2009*| 1,116   | 50 | 4.5   | 731  | 65.5 | 287 | 25.7 | 48 | 4.3  | 5  | 0.4 | 500  | 44.8 | 545 | 48.9 | 66 | 3.9  |
| Tapia et al. [59]       | 2011**| 168   | 2  | 1.2   | 76  | 45.2 | 64  | 38.1 | 26 | 15.5 | 1  | 0.6 | 51   | 30.4 | 90  | 53.6 | 26 | 15.4 |
| Brookman et al. [60]    | 2012*| 856     | 140| 16.3  | 493  | 57.6 | 177 | 20.7 | 46 | 5.4  | 39 | 4.5 | 450  | 52.6 | 248 | 29   | 119| 13.9 |
| Van Praet et al. [61]   | 2014*| 135     | 16 | 11.9  | 82  | 60.7 | 25  | 18.5 | 12 | 8.9  | 3  | 2.2 | 65   | 48.1 | 51  | 37.8 | 16 | 11.9 |
|                         | 2014**| 193   | 0  | 0    | 68  | 35.2 | 90  | 46.7 | 35 | 18.1 | 0  | 0    | 48   | 24.9 | 111 | 57.5 | 34 | 17.6 |
| Helpap et al. [62]      | 2016*| 580     | 0  | 0    | 111  | 19.1 | 391 | 67.5 | 78  | 13.4 | 0  | 0    | 18   | 3.1  | 467 | 80.5 | 95 | 16.4 |
| Xu et al. [63]          | 2017**| 237   | 0  | 0    | 86  | 36.3 | 107 | 45.1 | 44 | 18.6 | 0  | 0    | 66   | 27.8 | 116 | 49   | 55 | 23.2 |
| Danneman et al. [64]    | 2017*| 15,598  | 149| 0.9   | 8,448 | 54.2 | 6005 | 38.5 | 996 | 6.4  | 35 | 0.2 | 6,475 | 41.5 | 8,004 | 51.3 | 1,084| 7     |
| Current study           | 0    | 0      | 0  | 0    | 0   | 0    | 0  | 0    | 0  | 0    | 0  | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| Overall (weighted mean %) | 31,147 | 936 | 3.0 | 17,128 | 55.0 | 10,986 | 35.3 | 2,097 | 6.7 | 263 | 0.8 | 13,119 | 42.1 | 15,252 | 49.0 | 2,513 | 8.1 |

*Diagnosed with cancer by sextant biopsy; **Diagnosed with cancer by extended biopsies (≥ 10 core biopsies).
patients had a GS in biopsy between 5-6 (moderately) and 35.3% had a GS 7 (intermediate). However, these rates changed to 42.1% and 49.0% when RP specimens were evaluated. After using the weighted mean and the GS by groups (Table 6), we found that the overall Gleason biopsy between 2-4, 5-6, 7 and 8-10 presented 3.0%, 55.0%, 35.3% and 6.7% and in the surgical specimen presented 0.8%, 42.1%, 49.0% and 8.1%. The present study had a higher frequency of patients with intermediate GSs (43%) in biopsy than the literature review performed and after analysis of the surgical specimen increased considerably (87%).

After using RP as gold standard, SE, SP, positive and negative predictive value were calculated for needle biopsy graduation for each categorization scheme applied (Tables 3 and 4). Djavan et al. [40] in their study report that the SE decreases with the higher histological classification, because less and less the histologically higher graduated cancers are predicted with precision based on needle biopsy and the SP in general is lower for moderately differentiated cancers in needle biopsy, since many patients go from good to moderately differentiated, while some patients are actually “super graduates” and then change from poor to moderately differentiated cancer based on the prostatectomy specimen [40]. The independent accuracy of histological classification and categorization schemes ranged from 61.4 to 91.1% [40]. Overall, our study showed that SE increased with the higher histological classification, SP was low (33.4%) for poorly differentiated patients in scheme 2 and the accuracy of histological classification regardless of categorization varied from 44.0 to 76.0% (Table 4).

Despite our results, there are some points that could be improved in future studies, including a larger population sample with a GS well differentiated (2-4). Although the study is retrospective, the pathological descriptions are always rigorous and standardized for all patients with RP. More studies correlating pT staging with GS well differentiated (2-4) are needed to confirm whether this would affect the search results.

5. Conclusions

We conclude that there are differences in the concordance between GS in biopsy and in surgical specimen, and GS is also dependent on the experience of the pathologist. Although prostate needle biopsies are associated with significant graduation errors, they provide valuable information about pre-treatment histological pattern, reflecting the tumour potential.

After analyzing the characteristics of the patients and comparing them with several studies, we can point out that clinical data, needle biopsy, prostate-specific antigen and pathological characteristics are available tools for good therapeutic management, so it is up to the physician to make good use of them for effective therapeutic potential. Thus, it is evident that sextant biopsies using 18-gauge needle and the same group of pathologists showed acceptable match values (42%) between GS on biopsy and prostatectomy.

Acknowledgments

We are grateful to the Gabriel Araújo Souza for the formulation and structuring of the database in an internet platform, the team of the Nucleus of Cytopathology and Pathological Anatomy of the Hospital Base of the Federal District (NUCAP-HBDF), of the Clinical Body of Urology of the Hospital Base of the Federal District (HBDF) and the Research Center of the Hospital Base of the Federal District (HBDF) for their suggestion and assistance.

References

[1] Ferlay, J., et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. Lyon, France: IARC (IARC CancerBase, 11).
[2] Stewart, B. W., and Wild, C. P., eds. World Cancer Report: 2014. Lyon: IARC.
[3] Norberg, M., Egevad, L., Holmberg, L., Sparén, P., Norlén, B. J., and Busch, C. 1997. “The Sextant Protocol for Ultrasound-Guided Core Biopsies of the Prostate Underestimates the Presence of Cancer.” Urology 50 (4): 562-6. doi:10.1016/S0090-4295(97)00306-3.
[4] Nafie, S., Pal, R. P., Dormer, J. P., and Khan, M. A. 2014. “Transperineal Template Prostate Biopsies in Men with Raised PSA despite Two Previous Sets of Negative
Diagnostic Value between 1984 and 2018 of Transrectal Biopsy Guided by Ultrasoundography after Radical Prostatectomy

TRUS-guided Prostate Biopsies.” World J Urol 32 (4): 971-5. doi:10.1007/s00345-013-1225-x.

Humphrey, P. A. 2004. “Gleason Grading and Prognostic Factors in Carcinoma of the Prostate.” Mod Pathol 17: 292-306.

Montironi, R., Mazuccheli, R., Scarpelli, M., Lopez-Beltran, A., Fellegara, G., and Aliga, F. 2005. “Gleason Grading of Prostate cancer in Needle Biopsies or Radical Prostatectomy Specimens: Contemporary Approach, Current Clinical Significance and Sources of Pathology Discrepancies.” BJU Int 95: 1146-52.

Edge, S. B., and Compton, C. C. 2010. “The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM.” Ann Surg Oncol. 17 (6): 1471-4. doi: 10.1245/s10434-010-0985-4.

Gleason, D. F., and Mellinger, G. T. 1974. “The Veterans Administration Cooperative Urological Research Group. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.” J Urol 111: 58-64.

Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Häggman, M., et al. 2002. “A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer.” N Engl J Med 347: 781-9.

Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., et al. 2009. “Endocrine Treatment, with or without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/ SFUO-3): An Open Randomised Phase III Trial.” Lancet 373: 301-8.

Egevad, L., Granfors, T., Karlbery, L., Bergh, A., and Stattin, P. 2002. “Prognostic Value of the Gleason Score in Prostate Cancer.” BJU Int 89: 538-42.

Gleason, D. F., and Mellinger, G. 1974. “Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.” J Urol 111: 58-64.

Gleason, D. F. 1992. “Histologic Grading of Prostate Cancer: A Perspective.” Hum Pathol 23: 273-9.

Bain, G., Koch, M., and Hanson, J. 1982. “Feasibility of Grading Prostatic Carcinomas.” J Arch Pathol Lab Med 106: 265-7.

Ruijter, E., Van Leenders, G., Miller, G., Debruyne, F., and Van, D. K. C. 2015. “Errors in Histological Grading by Prostatic Needle Biopsy Specimens: Frequency and Predisposing Factors.” Journal of Pathology 192 (2): 229-33.

Allsbrook, W. C., Mangold, K. A., Johnson, M. H., Lane, R. B., Lane, C. G., Amin, M. B., et al. 2001. “Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: Urologic Pathologists.” Human Pathology 32 (1): 81-8.

Hodge, K. K., McNeal, J. E., Terris, M. K., and Stamey, T. A. 1989. “Random Systematic versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate.” J Urol 142: 71-4.

Kim, C. K. 2015. “Magnetic Resonance Imaging-Guided Prostate Biopsy: Present and Future.” Korean Journal of Radiology 16 (1): 90-8. doi:10.3348/jkr.2015.16.1.90.

Schröder, F. H., and Roobol, M. J. 2009. “Defining the Optimal Prostate Specific Antigen Threshold for the Diagnosis of Prostate Cancer.” Curr Opin Urol 19: 227-31.

Howlader, N., et al., ed. 2017. SEER Cancer Statistics Review, 1975-2014. Bethesda: National Cancer Institute. https://seer.cancer.gov/csr/1975_2014/.

Roche, J. B., Malavaud, B., Soulé, M., and Cournot, M. 2008. “Pathological Stage T3 Prostate Cancer after Radical Prostatectomy: A Retrospective Study of 246 Cases.” Prog Urol 18: 586-94.

Eduardo, et al. 2010. “Relação entre escore de Gleason e fatores prognósticos no adenocarcinoma acinar de próstata.” J Bras. Patol. Med. Lab., Rio de Janeiro 46 (1): 61-8.

Bahnson, R. R., Dresner, S. M., Gooding, W., and Becich, M. J. 1989. “Incidence and Prognostic Significance of Lymphatic and Vascular Invasion in Radical Prostatectomy Specimens.” Prostate 15 (2): 149-55.

Eble, J. N., et al. 2004. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, pp. 160-215.

Epstein, J. I., Allsbrook Jr, W. C., Amin, M. B., Egevad, L. L., and the ISUP Grading Committee. 2005. “The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.” Am J SurgPathol 29: 1228-42.

Srigley, J. R., et al. 2000. “Practice Protocol for the Examination of Specimens Removed from Patients with Carcinoma of the Prostate. A Publication of the Cancer Committee, College of American Pathologists.” ArchPathollabMed 124: 1034-9.

Mceal, J. E., Redwine, E. A., Freiha, F. S., and Stamey, T. A. 1988. “Zonal Distribution of Prostatic Adenocarcinoma. Correlation with Histologic Pattern and Direction of Spread.” Am J Surg Pathol 12: 897-906.

Torlakovic, G., Torlakovic, E., Skovlund, E., Nesland, J. M., Reith, A., and Danielsen, H. E. 2005. “Volume-Related Sequence of Tumor Distribution Pattern in Prostate Carcinoma: Importance of Posterior Midline Crossover in Predicting Tumor Volume, Extracapsular Extension, and Seminal Vesicle Invasion.” CroatMed J 46 (3): 429-35.
Followup.”

Adenocarcinomas of the Prostate with 5 Years of Multivariate Analysis of 185 Clinical Stage B

Humphrey, P. 2004. “Gleason Grading and Prognostic Weight, C. J., Ciezki, J. P., Reddy, C. A., Zhou, M., and Klein, E. A. 2006. “Perineural Invasion on Prostate Needle Biopsy Does Not Predict Biochemical Failure Following Brachytherapy for Prostate Cancer.” International Journal of Radiation Oncology, Biology, Physics 65 (2): 347-50.

Epstein, J. L., Carmichael, M., Partin, A. W., and Walsh, P. C. 1993. “Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup.” J Urol 149: 1478-81.

Humphrey, P. 2004. “Gleason Grading and Prognostic Factors in Carcinoma of the Prostate.” Mod Pathol 17: 292-306.

Montironi, R., Mazzucchelli, R., Santinelli, A., Scarpelli, M., Antonio López Beltran, and Bostwick, D. G. 2005. Incidentally Detected Prostate Cancer in Cystoprostatectomies: Pathological and Morphometric Comparison with Clinically Detected Cancer in Totally Embedded Specimens.” HumPathol 36: 646-54.

Miller, G. J., and Cygan, J. M. 1994. “Morphology of Prostate Cancer: The Effects of Multifocality on Histological Grade, Tumor Volume and Capsule Penetration.” J Urol 152: 1709-13.

Wheeler, T. M., Dilliglugil, O., Kattan, M. W., Arakawa, A., Soh, S., Suyama, K., et al. 1998. “Clinical and Pathological Significance of the Level and Extent of Capsular Invasion in Clinical Stage t1-2 Prostate Cancer.” Hum Pathol. 29 (8): 856-62.

Yamamoto, S., Kawakami, S., Yonese, J., Fujii, Y., Okhubo, Y., Suyama, T., et al. 2010. “Lymphovascular Invasion Is an Independent Predictor of Prostate-Specific Antigen Failure after Radical Prostatectomy in Patients with pT3aN0 Prostate Cancer.” International Journal of Urology 15 (10): 895-9.

Thickman, D., Speers, W. C., Philpott, P. J., et al. 1996. “Effect of the Number of Core Biopsies of the Prostate on Predicting Gleason Score of Prostate Cancer.” J Urol 156: 110-3.

Cookson, M. S., Fleshner, N. E., Soloway, S. M., et al. 1997. “Correlation between Gleason Score of Needle Biopsy and Radical Prostatectomy Myspecimen: Accuracy and Clinical Implications.” J Urol 157: 559-62.

Steinberg, D. M., Sauvageot, J., Piantadosi, S., and Epstein, J. I. 1997. “Correlation of Prostate Needle Biopsy and Radical Prostatectomy Gleason Grade in Academic and Community Settings.” American Journal of Surgical Pathology 21 (5): 566-76.

Danziger, M., Shevchuk, M., Antonescu, C., Matthews, G. J., and Fracchia, J. A. 1997. “Predictive Accuracy of Transrectal Ultrasound-Guided Prostate Biopsy: Correlations to Matched Prostatectomy Specimens.” Urology 49 (6): 863-7.

Djavan, B., Kadesky, K., Klopk, B., et al. 1998. “Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens.” EurUrol 33: 261-70.

Carlson, G. D., Calvanese, C. B., Kahane, H., and Epstein, J. I. 1998. “Accuracy of Biopsy Gleason Scores from a Large Uropathology Laboratory: Use of a Diagnostic Protocol to Minimize Observer Variability.” Urology 51 (4): 525-9.

Cury, J., Srougi, M., Leite, K. R. M., Lopes, L. H. C., Carneiro, P. C. 1999. “Correlation between Histologic Biopsy Grading and Radical Prostatectomy Specimen in Prostate Cancer.” Revista do Colégio Brasileiro de Cirurgiões 26 (1), ISSN 0100-6991.

King, C. R. 2015. “Patterns of Prostate Cancer Biopsy Grading: Trends and Clinical Implications.” International Journal of Cancer 90 (6): 305-11.

Fukagai, T., Namiki, T., Namiki, H., Carlile, R. G., and Yoshida, H. 2001. “Discrepancies between Gleason Scores of Needle Biopsy and Radical Prostatectomy Specimens.” Pathol Int 51: 364-70.

Lattouf, J. B., and Saad, F. 2015. “Gleason Score on Biopsy: Is It Reliable for Predicting the Final Grade on Pathology?” Bju International 90 (7): 694-8.

San Francisco, I. F., DeWolf, W. C., Rosen, S., et al. 2003. “Extended Prostate Needle Biopsy Improves Concordance of Gleason Grading between Prostate Needle Biopsy and Radical Prostatectomy.” J Urol 169: 136-40.

Emiliozzi, P., Maymone, S., Paterno, A., Scarpone, P., Amini, M., Proietti, G., et al. 2004. “Increased Accuracy of Biopsy Gleason Score Obtained by Extended Needle Biopsy.” The Journal of Urology 172 (6): 2224-6.

Divrik, R. T., Eroglu, A., Sahin, A., Zorlu, F., and Ozen, H. 2007. “Increasing the Number of Biopsies Increases the Concordance of Gleason Scores of Needle Biopsies and Prostatectomy Specimens.” Urologic Oncology Seminars & Original Investigations 25 (5): 376-82.

Leite, K. R. M., Camara-Lopes, L. H. A., Dall'Oglio, M. F., Cury, J., Antunes, A. A., SaUDO, A., et al. 2009. “Upgrading the Gleason Score in Extended Prostate Biopsy: Implications for Treatment Choice.” International Journal of Radiation Oncology Biology Physics 73 (2): 353-6.

Kvåle, R., Møller, B., Wahlqvist, R., Fossa, S. D., Berner, A., Busch, C., Kyrkild, A. E., Svindland, A., Viset, T., and Halvorsen, O. J. 2009. “Concordance between Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens: A Population-Based Study.” BJU Int. 103 (12): 1647-54.
Diagnostic Value between 1984 and 2018 of Transrectal Biopsy Guided by Ultrasonography after Radical Prostatectomy

[51] Moussa, A. S., Li, J., Soriano, M., Klein, E. A., Dong, F., and Jones, J. S. 2009. “Prostate Biopsy Clinical and Pathological Variables That Predict Significant Grading Changes in Patients with Intermediate and High Grade Prostate Cancer.” BJU Int. 103 (1): 43-8.

[52] Helpap, B., Ringli, D., Tonhauser, J., Poser, I., Breul, J., Gevensleben, H., and Seifert, H. H. 2016. “The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.” Pathol Oncol Res. 22 (2): 349-56.

[53] Garnett, J. E., Oyasu, R., and Grayhack, J. T. 1983. “The Accuracy of Diagnostic Biopsy Specimens in Predicting Tumor Grades by Gleason’s Classification of Radical Prostatectomy Specimens.” J Urol 131: 690-3.

[54] Mills, S. E., and Fowler, J. E. 1986. “Gleason Histologic Grading of Prostatic Carcinoma. Correlations between Biopsy and Prostatectomy Specimens.” Cancer 57: 346-9.

[55] King, C. R., Mcneal, J. E., Gill, H., and Presti, J. C. 2004. “Extended Prostate Biopsy Scheme Improves Reliability of Gleason Grading: Implications for Radiotherapy Patients.” International Journal of Radiation Oncology Biology Physics 59 (2): 386-91.

[56] Chun, K. H., Briganti, A., Shariat, S. F., Graefen, M., Montorsi, F., Erbersdobler, A., et al. 2006. “Significant Upgrading Affects a Third of Men Diagnosed with Prostate Cancer: Predictive Nomogram and Internal Validation.” BJU international 98 (2): 329-34.

[57] Fine, S. W., and Epstein, J. I. 2008. “A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score.” The Journal of Urology 179 (4): 1335-9.

[58] Fanning, D. M., Kay, E., Fan, Y., Fitzpatrick, J. M., and Watson, R. W. G. 2009. “Prostate Cancer Grading: The Effect of Stratification of Needle Biopsy Gleason Score 4+3 as High or Intermediate Grade.” BJU International 105 (5): 631-5. doi: 10.1111/j.1464-410X.2009.08810.x Epub 2009 Sep 3.

[59] Tapia, O., Bellolio, E., Roa, J. C., Guzmán, P., Villaseca, M., and Araya, J. C. 2011. “Concordance between Gleason Scores of Trans Rectal Biopsies and the Surgical Piece of Radical Prostatectomy.” Revista Médica De Chile 139 (2): 171-6.

[60] Brookman-May, S., May, M., Wieland, W. F., Lebentrau, S., Gunia, S., Koch, S., et al. 2012. “Should We Abstain from Gleason Score 2–4 in the Diagnosis of Prostate Cancer? Results of a German Multicentre Study.” World Journal of Urology 30 (1): 97-103.

[61] Van Praet, C., Libbrecht, L., D’Hondt, F., Decaestecker, K., Fonteyne, V., Verschueren, S., et al. 2014. “Agreement of Gleason Score on Prostate Biopsy and Radical Prostatectomy Specimen: Is There Improvement with Increased Number of Biopsy Cylinders and the 2005 Revised Gleason Scoring?” Clinical Genitourinary Cancer 12 (3): 160-6.

[62] Helpap, B., Ringli, D., Tonhauser, J., Poser, I., Breul, J., Gevensleben, H., and Seifert, H. H. 2015. “The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.” Pathol Oncol Res. 22 (2): 349-56.

[63] Xu, H., Bai, P. D., Hu, M. B., Mao, S. H., Zhu, W. H., Hu, J. M., Liu, S. H., Yang, T., Hou, J. Y., Hu, Y., Ding, Q., and Jiang, H. W. 2016. “Gleason Sum Upgrading between Biopsy and Radical Prostatectomy in Chinese Population: Updated Nomograms.” Actas Urol Esp. 41 (3): 162-71.

[64] Danneman, D., Drevin, L., Delahunt, B., Samaratunga, H., Robinson, D., Bratt, O., et al. 2017. “The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide Trends 2000-2012.” BJU International 119 (1): 50-6.

[65] Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., et al. 1993. “The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer.” The Journal of Urology 150 (1): 110-4.

[66] Epstein, J. I., Pizov, G., Steinberg, G. D., Carter, H. B., Pitcock, R., Armas, O. A., et al. 1992. “Correlation of Prostate Cancer Nuclear Deoxyribonucleic Acid, Size, Shape and Gleason Grade with Pathological Stage at Radical Prostatectomy.” The Journal of Urology 148 (1): 87-91.